Have Questions?

Global Headquarters

Tel: +44 (0)20 7377 0800
Fax: +44 (0)20 7349 5157

North America

Tel: 1-617-573-9450
Fax: 1-617-573-9542


Tel: +81 (0)80-1164-4754

Request a Demo

What our customers are saying

When I think of the future, I think of EvaluatePharma

Senior Director,
Global pharmaceutical company

EP Vantage Pharma & Biotech 2016 Preview

EP Vantage 2016 Preview EP Vantage 2016 Preview EP Vantage 2016 Preview

Download Report

EP Vantage Pharma & Biotech 2016 Preview

Despite the recent downturn in investor sentiment in the pharma and biotech sectors, 2016 is set to see the sector’s research and development productivity continue to grow with new drug launches and a limited impact of patent expiries.

According to EP Vantage’s new report, Pharma & Biotech 2016 Preview, 2016 will see:

  • The launch of 12 blockbusters
  • Pfizer overtake Novartis to be industry’s biggest company by sales - even without Allergan
  • AstraZenca slip to the bottom of the top 10 biggest companies league table
  • Humira to remain industry’s biggest selling drug
  • Older therapies such as oncolytic viruses and vaccines that have so far disappointed as monotherapies might benefit from the combination approach
  • AbbVie and AstraZeneca become the companies facing the biggest patent risks in 2016

Press Release

Confirm your details on form below to download this report